Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of several retinal eye disorders and is a biosimilar to EYLEA (aflibercept) 2 mg. Commenting on the launch, Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, "The launch of Yesafili in the U.S. marks an important step in expanding the global availability of biosimilar aflibercept 2 mg for patients with eye conditions. U.S. sales of aflibercept reached approximately USD 5.89 billion in 2023, highlighting the significant demand for therapies targeting retinal diseases. Yesafili is indicated in the U.S. for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). As with other intravitreal VEGF inhibitors, the product carries warnings regarding endophthalmitis, retinal detachment, retinal vasculitis, increased intraocular pressure, and the potential risk of arterial thromboembolic events.